MDB
MCID: MDL005
MIFTS: 77

Medulloblastoma (MDB) malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Medulloblastoma

Aliases & Descriptions for Medulloblastoma:

Name: Medulloblastoma 54 12 50 56 66 29 13 52 42 14 69
Localized Primitive Neuroectodermal Tumor 12 69
Classic Medulloblastoma 56 69
Cpnet 12 69
Mdb 50 66
Infratentorial Primitive Neuroectodermal Tumor 12
Medulloblastoma, with Extensive Nodularity 69
Medulloblastoma with Extensive Nodularity 56
Desmoplastic/nodular Medulloblastoma 56
Neuroectodermal Tumors, Primitive 42
Medulloblastoma, Desmoplastic 54
Medulloblastoma Desmoplastic 52
Desmoplastic Medulloblastoma 69
Brain Medulloblastoma 12
Cns Pnet 12
Mben 56

Characteristics:

Orphanet epidemiological data:

56
medulloblastoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-9/1000000 (United States); Age of onset: All ages; Age of death: adolescent,adult,early childhood,infantile,late childhood,young Adult;
classic medulloblastoma
Age of onset: Childhood;
desmoplastic/nodular medulloblastoma
Inheritance: Not applicable; Age of onset: Adult;
medulloblastoma with extensive nodularity
Inheritance: Not applicable; Age of onset: Childhood,Infancy; Age of death: normal life expectancy;

HPO:

32
medulloblastoma:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

OMIM 54 155255
Disease Ontology 12 DOID:0050902
ICD10 via Orphanet 34 C71.6
UMLS via Orphanet 70 C0751291 C0025149
MESH via Orphanet 43 D008527

Summaries for Medulloblastoma

OMIM : 54 Medulloblastoma is the most common brain tumor in children. It accounts for 16% of all pediatric brain tumors, and 40%... (155255) more...

MalaCards based summary : Medulloblastoma, also known as localized primitive neuroectodermal tumor, is related to childhood medulloblastoma and childhood central nervous system primitive neuroectodermal neoplasm, and has symptoms including headache, vomiting and gait ataxia. An important gene associated with Medulloblastoma is SUFU (SUFU Negative Regulator Of Hedgehog Signaling), and among its related pathways/superpathways are ERK Signaling and Activation of cAMP-Dependent PKA. The drugs Ranibizumab and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include brain, cerebellum and bone, and related phenotypes are Decreased viability in esophageal squamous lineage and digestive/alimentary

Disease Ontology : 12 An infratentorial cancer that is located in the lower part of the brain and is a type of primitive neuroectodermal tumor.

UniProtKB/Swiss-Prot : 66 Medulloblastoma: Malignant, invasive embryonal tumor of the cerebellum with a preferential manifestation in children.

Wikipedia : 71 Medulloblastoma (/məˌdʌloʊblæˈstoʊmə/) is the most common type of pediatric malignant primary... more...

Related Diseases for Medulloblastoma

Diseases in the Medulloblastoma family:

Adult Medulloblastoma Medulloblastoma, Ptch2-Related
Medulloblastoma, Sufu-Related

Diseases related to Medulloblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 216)
id Related Disease Score Top Affiliating Genes
1 childhood medulloblastoma 33.7 GFAP MYC MYCN OTX2 SYP TP53
2 childhood central nervous system primitive neuroectodermal neoplasm 32.0 CTNNB1 GFAP GLI1 MYCN PTCH1 SUFU
3 basal cell nevus syndrome 31.9 APC BRCA2 CDCA7L CTNNB1 DAB2IP DMBT1
4 pineoblastoma 30.2 GFAP MYCN SYP TP53
5 neuroblastoma 29.8 CTNNB1 MYC MYCN SYP TP53
6 large cell medulloblastoma 12.1
7 adult medulloblastoma 12.0
8 cerebellar medulloblastoma 12.0
9 melanotic medulloblastoma 12.0
10 nodular medulloblastoma 11.9
11 cerebellar vermis medulloblastoma 11.9
12 brain stem medulloblastoma 11.7
13 medulloblastoma, sufu-related 11.7
14 anaplastic/large cell medulloblastoma 11.7
15 medulloblastoma, ptch2-related 11.7
16 mismatch repair cancer syndrome 11.1
17 cerebellar liponeurocytoma 11.1
18 adult central nervous system primitive neuroectodermal neoplasm 11.0
19 rhabdoid tumors, somatic 10.9
20 central nervous system primitive neuroectodermal neoplasm 10.8
21 blastoma 10.8
22 rhabdoid tumor predisposition syndrome 2 10.8
23 hemorrhagic proctocolitis 10.5 CTNNB1 GFAP MYC
24 bronchitis 10.5 GFAP PTCH1 TP53
25 basal cell carcinoma 1 10.5 PTCH1 PTCH2 SMO
26 diabetes hypogonadism deafness mental retardation 10.5 GFAP MYCN SYP
27 paternal uniparental disomy of chromosome 1 10.5 GFAP SYP TP53
28 vulvar benign neoplasm 10.5 GFAP SYP TP53
29 bone benign neoplasm 10.5 CTNNB1 SYP TP53
30 blood group incompatibility 10.5 GFAP SYP TP53
31 asperger syndrome 10.5 APC CTNNB1 MYC TP53
32 cervical benign neoplasm 10.5 GFAP PTCH1 SYP TP53
33 mast-cell sarcoma 10.5 GFAP SUFU SYP TP53
34 olfactory neuroblastoma 10.5 GFAP SYP TP53
35 intestinal pseudo-obstruction 10.5 CTNNB1 GFAP GLI1 PTCH1 SUFU
36 colonic pseudo-obstruction 10.5 MYC MYCN NTRK3 PTCH1 SUFU
37 brain stem astrocytic neoplasm 10.5 GFAP SYP TP53
38 t-cell adult acute lymphocytic leukemia 10.4 PTCH1 PTCH2 SYP
39 temporal lobe neoplasm 10.4 CTNNB1 GFAP SYP
40 brain oligodendroglioma 10.4 GFAP SYP TP53
41 clear cell meningioma 10.4 GFAP PTCH1 SUFU SYP TP53
42 duodenal ulcer 10.4 MYC MYCN TP53
43 arthus reaction 10.4 GFAP SYP TP53
44 childhood brain germinoma 10.4 MYC MYCN SYP TP53
45 liver fibrosarcoma 10.4 GFAP TP53
46 fibromatosis, gingival, 1 10.4 APC CTNNB1 MYCN
47 clear cell variant infiltrating bladder urothelial carcinoma 10.4 GFAP PTCH1 SUFU SYP TP53
48 prostate rhabdomyosarcoma 10.4 GLI1 MYCN PTCH1 TP53
49 pancreatic cancer 10.4 GFAP SYP TP53
50 pacinian tumor 10.4 GFAP SYP TP53

Graphical network of the top 20 diseases related to Medulloblastoma:



Diseases related to Medulloblastoma

Symptoms & Phenotypes for Medulloblastoma

Symptoms by clinical synopsis from OMIM:

155255

Clinical features from OMIM:

155255

Human phenotypes related to Medulloblastoma:

32
id Description HPO Frequency HPO Source Accession
1 medulloblastoma 32 HP:0002885

UMLS symptoms related to Medulloblastoma:


headache, vomiting, gait ataxia, cerebellar ataxia/dyskinesia

GenomeRNAi Phenotypes related to Medulloblastoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.36 DAB2IP DMBT1 GFAP GLI1 MYCN SMO

MGI Mouse Phenotypes related to Medulloblastoma:

44 (show all 23)
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.43 DMBT1 GFAP GLI1 MYC MYCN OTX2
2 behavior/neurological MP:0005386 10.42 BRCA2 CTNNB1 GFAP GLI1 MYC MYCN
3 cellular MP:0005384 10.41 CTNNB1 DAB2IP DMBT1 GFAP GLI1 MYC
4 growth/size/body region MP:0005378 10.41 APC BRCA2 CTNNB1 GFAP GLI1 MYC
5 mortality/aging MP:0010768 10.39 APC BRCA2 CTNNB1 DMBT1 GFAP GLI1
6 nervous system MP:0003631 10.39 CTNNB1 DAB2IP GFAP GLI1 MYC MYCN
7 cardiovascular system MP:0005385 10.38 APC CTNNB1 GFAP MYC MYCN NTRK3
8 homeostasis/metabolism MP:0005376 10.36 APC BRCA2 CTNNB1 DAB2IP DMBT1 GFAP
9 embryo MP:0005380 10.35 DMBT1 GLI1 MYC MYCN OTX2 PTCH1
10 craniofacial MP:0005382 10.29 APC CTNNB1 GLI1 MYC MYCN OTX2
11 normal MP:0002873 10.28 APC BRCA2 CTNNB1 GFAP GLI1 MYC
12 muscle MP:0005369 10.24 TP53 ZIC1 APC CTNNB1 GFAP MYC
13 limbs/digits/tail MP:0005371 10.22 APC BRCA2 CTNNB1 GLI1 MYC MYCN
14 neoplasm MP:0002006 10.18 APC BRCA2 CTNNB1 DMBT1 GLI1 MYC
15 hearing/vestibular/ear MP:0005377 10.16 APC CTNNB1 DMBT1 MYC NTRK3 OTX2
16 integument MP:0010771 10.14 SUFU TP53 APC BRCA2 CTNNB1 MYC
17 no phenotypic analysis MP:0003012 10.13 APC CTNNB1 DAB2IP GLI1 MYC MYCN
18 reproductive system MP:0005389 9.96 APC BRCA2 CTNNB1 PTCH2 TP53 GLI1
19 pigmentation MP:0001186 9.91 APC CTNNB1 MYC OTX2 PTCH1 SUFU
20 renal/urinary system MP:0005367 9.87 APC CTNNB1 DMBT1 GLI1 MYCN PTCH1
21 respiratory system MP:0005388 9.81 CTNNB1 GLI1 MYCN NTRK3 OTX2 PTCH1
22 skeleton MP:0005390 9.7 APC BRCA2 CTNNB1 MYC MYCN OTX2
23 vision/eye MP:0005391 9.32 SUFU TP53 APC CTNNB1 GFAP MYCN

Drugs & Therapeutics for Medulloblastoma

Drugs for Medulloblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 897)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
4
Vindesine Approved Phase 4,Phase 3,Phase 2 59917-39-4, 53643-48-4 40839
5
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 5754 657311
6
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
8
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
9
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
10
Carboplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
11
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 33419-42-0 36462
12
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
13
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
14
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
15
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99011-02-6 57469
16
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
17
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
18
Mesna Approved Phase 4,Phase 3,Phase 2,Phase 1 3375-50-6 598
19
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
20
Thiotepa Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 52-24-4 5453
21
Somatostatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 38916-34-6, 51110-01-1 53481605
22
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 1,Phase 2 106-60-5 137
23
Sunitinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 341031-54-7, 557795-19-4 5329102
24
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 124-94-7 31307
25
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 1 302962-49-8 3062316
26
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
27
Trametinib Approved Phase 4,Phase 3,Phase 2,Phase 1 871700-17-3 11707110
28
Aldesleukin Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 85898-30-2, 110942-02-4
29
Itraconazole Approved, Investigational Phase 4,Phase 1 84625-61-6 55283
30
lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 108736-35-2
31
Etanercept Approved, Investigational Phase 4,Phase 2 185243-69-0
32
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1 53608-75-6
33
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 946414-94-4
34 Piracetam Approved Phase 4,Phase 2 7491-74-9
35
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 99-66-1 3121
36
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 1 179324-69-7 387447 93860
37
Gefitinib Approved, Investigational Phase 4,Phase 2,Phase 1 184475-35-2 123631
38
Ramucirumab Approved, Investigational Phase 4,Phase 2,Phase 1 947687-13-0
39
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 149647-78-9 5311
40
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
41
Diazoxide Approved Phase 4,Phase 3,Phase 2 364-98-7 3019
42
Doxazosin Approved Phase 4 74191-85-8 3157
43
Phenoxybenzamine Approved Phase 4 59-96-1 4768
44
Nicotine Approved Phase 4 54-11-5 942 89594
45
Ceritinib Approved Phase 4,Phase 2,Phase 1,Early Phase 1 1032900-25-6
46
Crizotinib Approved Phase 4,Phase 3,Phase 2,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
47
Olaparib Approved Phase 4,Phase 2,Phase 1 763113-22-0 23725625
48
Palbociclib Approved Phase 4,Phase 1,Phase 2 571190-30-2 11431660 5005498 5330286
49
Zinc Approved Phase 4,Phase 1 7440-66-6 32051 23994
50
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 4457)
id Name Status NCT ID Phase
1 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4
2 Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy Unknown status NCT00454935 Phase 4
3 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4
4 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
5 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4
6 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4
7 Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors Completed NCT01595009 Phase 4
8 Somatuline Autogel Preference and Health Economy Study Completed NCT00681187 Phase 4
9 CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma Completed NCT02319486 Phase 4
10 Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma Completed NCT01253759 Phase 4
11 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4
12 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4
13 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4
14 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
15 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4
16 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4
17 HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Recruiting NCT02875314 Phase 4
18 Nonfunctional Pancreatic NET and PET Imaging Recruiting NCT02621541 Phase 4
19 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4
20 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Recruiting NCT02626065 Phase 4
21 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Recruiting NCT02451488 Phase 4
22 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4
23 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4
24 Phenoxybenzamine Versus Doxazosin in PCC Patients Recruiting NCT01379898 Phase 4
25 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4
26 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4
27 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Recruiting NCT02685592 Phase 4
28 Radiolabeled Molecules for Medullary Thyroid Cancer Recruiting NCT01915485 Phase 4
29 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4
30 Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET Active, not recruiting NCT03083210 Phase 4
31 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
32 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients Active, not recruiting NCT02075606 Phase 4
33 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4
34 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Active, not recruiting NCT02379000 Phase 4
35 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4
36 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4
37 Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab Active, not recruiting NCT01515189 Phase 4
38 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
39 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Not yet recruiting NCT02933333 Phase 4
40 Seizure Treatment in Glioma Not yet recruiting NCT03048084 Phase 4
41 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4
42 Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4
43 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4
44 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4
45 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
46 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4
47 Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma Unknown status NCT00053872 Phase 3
48 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
49 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3
50 Quality of Life in Patients Who Have Undergone Previous Treatment for Primitive Neuroectodermal Tumors Unknown status NCT00278239 Phase 3

Search NIH Clinical Center for Medulloblastoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: medulloblastoma

Genetic Tests for Medulloblastoma

Genetic tests related to Medulloblastoma:

id Genetic test Affiliating Genes
1 Medulloblastoma 29

Anatomical Context for Medulloblastoma

MalaCards organs/tissues related to Medulloblastoma:

39
Brain, Cerebellum, Bone, Bone Marrow, Thyroid, Breast, Endothelial

The Foundational Model of Anatomy Ontology organs/tissues related to Medulloblastoma:

18
The Lower Part Of The Brain

Publications for Medulloblastoma

Articles related to Medulloblastoma:

(show top 50) (show all 1511)
id Title Authors Year
1
Differential Expression of microRNAs in Medulloblastoma and the Potential Functional Consequences. ( 28481393 )
2017
2
Potential role of long non-coding RNA ANRIL in pediatric medulloblastoma through promotion on proliferation and migration by targeting miR-323. ( 28513871 )
2017
3
PTEN Signaling in the Postnatal Perivascular Progenitor Niche Drives Medulloblastoma Formation. ( 27815386 )
2017
4
Concurrent paediatric medulloblastoma and Chiari I malformation with syringomyelia. ( 28432427 )
2017
5
Synergistic anti-cancer effects of epigenetic drugs on medulloblastoma cells. ( 28429280 )
2017
6
Chemoradiation impairs normal developmental cortical thinning in medulloblastoma. ( 28534154 )
2017
7
Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells. ( 28504719 )
2017
8
PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis. ( 28283778 )
2017
9
The expression of FAT1 is associated with overall survival in children with medulloblastoma. ( 27834469 )
2017
10
Study of hTERT and Histone 3 Mutations in Medulloblastoma. ( 27694758 )
2017
11
Pyruvate kinase inhibits proliferation during postnatal cerebellar neurogenesis and suppresses medulloblastoma formation. ( 28515149 )
2017
12
The polo-like kinase 4 gene (PLK4) is overexpressed in pediatric medulloblastoma. ( 28497182 )
2017
13
High programmed cell death 1 ligand-1 expression: association with CD8+ T-cell infiltration and poor prognosis in human medulloblastoma. ( 28474991 )
2017
14
Response Assessment in Medulloblastoma and Leptomeningeal Seeding Tumors: Recommendations from the Response Assessment in Pediatric Neuro-Oncology Committee. ( 28449033 )
2017
15
Metabolic analysis of radioresistant medulloblastoma stem-like clones and potential therapeutic targets. ( 28426747 )
2017
16
Imaging mass spectrometry identifies prognostic ganglioside species in rodent intracranial transplants of glioma and medulloblastoma. ( 28463983 )
2017
17
In vivo bioluminescence imaging using orthotopic xenografts towards patient's derived-xenograft Medulloblastoma models. ( 27982543 )
2017
18
The kinesin KIF14 is overexpressed in medulloblastoma and downregulation of KIF14 suppressed tumor proliferation and induced apoptosis. ( 28504687 )
2017
19
Tailoring Medulloblastoma Treatment Through Genomics: Making a Change, One Subgroup at a Time. ( 28475368 )
2017
20
Corrigendum: Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma. ( 28429760 )
2017
21
Large cell/anaplastic medulloblastoma is associated with poor prognosis-a retrospective analysis at a single institute. ( 28488086 )
2017
22
Severe vincristine-induced polyneuropathy in a teenager with anaplastic medulloblastoma and undiagnosed Charcot-Marie-Tooth disease. ( 28438772 )
2017
23
A review of dosimetric and toxicity modeling of proton versus photon craniospinal irradiation for pediatrics medulloblastoma. ( 28509599 )
2017
24
Albumin nanoparticles for glutathione-responsive release of cisplatin: New opportunities for medulloblastoma. ( 27956195 )
2017
25
Risk factors for development of postoperative cerebellar mutism syndrome in children after medulloblastoma surgery. ( 28498095 )
2017
26
Comprehensive analysis of a microRNA expression profile in pediatric medulloblastoma. ( 28440450 )
2017
27
Suppression of GLI sensitizes medulloblastoma cells to mitochondria-mediated apoptosis. ( 27601167 )
2016
28
Identification of a novel inherited ALK variant M1199L in the WNT type of medulloblastoma. ( 27179218 )
2016
29
RalA is overactivated in medulloblastoma. ( 27566179 )
2016
30
Radiation Sensitivity in a Preclinical Mouse Model of Medulloblastoma Relies on the Function of the Intrinsic Apoptotic Pathway. ( 27197166 )
2016
31
Functional Genomics Identifies Tis21-Dependent Mechanisms and Putative Cancer Drug Targets Underlying Medulloblastoma Shh-Type Development. ( 27965576 )
2016
32
Ex vivo miRNome analysis in Ptch1+/- cerebellum granule cells reveals a subset of miRNAs involved in radiation-induced medulloblastoma. ( 27626168 )
2016
33
Blood-Brain Barrier Breakdown Determines Differential Therapeutic Outcome in Genetically Diverse Forms of Medulloblastoma. ( 27070693 )
2016
34
FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. ( 27625374 )
2016
35
Reprogramming medulloblastoma-propagating cells via combined antagonism of Sonic Hedgehog and CXCR4. ( 28031228 )
2016
36
Sonic Hedgehog Signaling Drives Mitochondrial Fragmentation by Suppressing Mitofusins in Cerebellar Granule Neuron Precursors and Medulloblastoma. ( 26446920 )
2016
37
Postoperative radiotherapy for paediatric medulloblastoma. ( 27523622 )
2016
38
Cerebellopontine angle medulloblastoma with extensive nodularity in a child: case report and review of the literature. ( 28013334 )
2016
39
SU-F-T-218: Validation of An In-Vivo Proton Range Verification Method for Reducing the Risk of Permanent Alopecia in the Treatment of Pediatric Medulloblastoma. ( 28046677 )
2016
40
Norrin/Frizzled4 signalling in the preneoplastic niche blocks medulloblastoma initiation. ( 27823583 )
2016
41
A case of Cushing ulcer in an 8-month-old patient with medulloblastoma. ( 27186526 )
2016
42
The therapeutic potential of natural killer cells to target medulloblastoma. ( 27144504 )
2016
43
Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters. ( 27863192 )
2016
44
Medulloblastoma in an elderly patient: A case report and literature review. ( 27588198 )
2016
45
Societal preferences in the treatment of pediatric medulloblastoma: Balancing risk of death and quality of life. ( 27917595 )
2016
46
Medulloblastoma-associated DDX3 variant selectively alters the translational response to stress. ( 27058758 )
2016
47
IDO1 involvement in mTOR pathway: A molecular mechanism of resistance to mTOR targeting in medulloblastoma. ( 27174915 )
2016
48
MPS1 kinase as a potential therapeutic target in medulloblastoma. ( 27633003 )
2016
49
Unexpected and sudden death due to undiagnosed medulloblastoma in twin pregnancy: A case report. ( 27595435 )
2016
50
Adult medulloblastoma: A rare case report and literature review. ( 27512610 )
2016

Variations for Medulloblastoma

UniProtKB/Swiss-Prot genetic disease variations for Medulloblastoma:

66
id Symbol AA change Variation ID SNP ID
1 APC p.Ala1296Val VAR_017653
2 APC p.Val1472Ile VAR_017654
3 APC p.Ser1495Gly VAR_017655
4 CTNNB1 p.Ser33Phe VAR_017617 rs121913400
5 CTNNB1 p.Ser37Ala VAR_017624 rs121913228

ClinVar genetic disease variations for Medulloblastoma:

6 (show top 50) (show all 84)
id Gene Variation Type Significance SNP ID Assembly Location
1 SUFU NM_016169.3(SUFU): c.44C> T (p.Pro15Leu) single nucleotide variant Pathogenic rs28942088 GRCh37 Chromosome 10, 104263953: 104263953
2 SUFU SUFU, 1-BP INS, 143A insertion Pathogenic
3 SUFU NM_016169.3(SUFU): c.1022+1G> A single nucleotide variant Pathogenic rs587776578 GRCh37 Chromosome 10, 104359302: 104359302
4 SUFU SUFU, 2.5-Mb DEL deletion Pathogenic
5 SUFU NM_016169.3(SUFU): c.71delC (p.Pro24Argfs) deletion Pathogenic rs587776579 GRCh37 Chromosome 10, 104263980: 104263980
6 SUFU SUFU, 1-BP INS, 71C insertion Pathogenic
7 PTCH2 NM_001166292.1(PTCH2): c.1172_1173delCT (p.Ser391Terfs) deletion Pathogenic rs56126236 GRCh37 Chromosome 1, 45295116: 45295117
8 BRCA2 NM_000059.3(BRCA2): c.658_659delGT (p.Val220Ilefs) deletion Pathogenic rs80359604 GRCh37 Chromosome 13, 32903606: 32903607
9 BRCA2 NM_000059.3(BRCA2): c.5645C> G (p.Ser1882Ter) single nucleotide variant Pathogenic rs80358785 GRCh37 Chromosome 13, 32914137: 32914137
10 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
11 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
12 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
13 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
14 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
15 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
16 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
17 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
18 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
19 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
20 CTNNB1 NM_001904.3(CTNNB1): c.95A> G (p.Asp32Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913396 GRCh37 Chromosome 3, 41266098: 41266098
21 CTNNB1 NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
22 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh37 Chromosome 3, 41266097: 41266097
23 CTNNB1 NM_001904.3(CTNNB1): c.98C> T (p.Ser33Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
24 CTNNB1 NM_001904.3(CTNNB1): c.101G> A (p.Gly34Glu) single nucleotide variant Pathogenic/Likely pathogenic rs28931589 GRCh37 Chromosome 3, 41266104: 41266104
25 CTNNB1 NM_001904.3(CTNNB1): c.110C> T (p.Ser37Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
26 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
27 PIK3CA NM_006218.3(PIK3CA): c.1637A> G (p.Gln546Arg) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 GRCh37 Chromosome 3, 178936095: 178936095
28 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
29 SUFU NM_016169.3(SUFU): c.111delC (p.Tyr38Thrfs) deletion Pathogenic rs863224925 GRCh37 Chromosome 10, 104264020: 104264020
30 FGFR1 NM_023110.2(FGFR1): c.1638C> A (p.Asn546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs779707422 GRCh37 Chromosome 8, 38274849: 38274849
31 FGFR1 NM_023110.2(FGFR1): c.1966A> G (p.Lys656Glu) single nucleotide variant Pathogenic/Likely pathogenic rs869320694 GRCh37 Chromosome 8, 38272308: 38272308
32 TP53 NM_000546.5(TP53): c.818G> C (p.Arg273Pro) single nucleotide variant Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
33 TP53 NM_000546.5(TP53): c.743G> T (p.Arg248Leu) single nucleotide variant Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
34 TP53 NM_000546.5(TP53): c.743G> C (p.Arg248Pro) single nucleotide variant Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
35 NRAS NM_002524.4(NRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
36 IDH1 NM_005896.3(IDH1): c.395G> T (p.Arg132Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh37 Chromosome 2, 209113112: 209113112
37 IDH1 NM_001282387.1(IDH1): c.394C> T (p.Arg132Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
38 IDH1 NM_001282387.1(IDH1): c.394C> G (p.Arg132Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
39 IDH1 NM_001282387.1(IDH1): c.394C> A (p.Arg132Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
40 CTNNB1 NM_001904.3(CTNNB1): c.110C> A (p.Ser37Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
41 PIK3CA NM_006218.3(PIK3CA): c.1637A> C (p.Gln546Pro) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 GRCh37 Chromosome 3, 178936095: 178936095
42 PIK3CA NM_006218.3(PIK3CA): c.1637A> T (p.Gln546Leu) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 GRCh37 Chromosome 3, 178936095: 178936095
43 SMO NM_005631.4(SMO): c.1417G> C (p.Asp473His) single nucleotide variant Pathogenic rs17710891 GRCh37 Chromosome 7, 128849189: 128849189
44 TP53 NM_001126112.2(TP53): c.746G> C (p.Arg249Thr) single nucleotide variant Likely pathogenic rs587782329 GRCh37 Chromosome 17, 7577535: 7577535
45 CTNNB1 NM_001904.3(CTNNB1): c.94G> C (p.Asp32His) single nucleotide variant Likely pathogenic rs28931588 GRCh37 Chromosome 3, 41266097: 41266097
46 CTNNB1 NM_001904.3(CTNNB1): c.94G> A (p.Asp32Asn) single nucleotide variant Likely pathogenic rs28931588 GRCh37 Chromosome 3, 41266097: 41266097
47 CTNNB1 NM_001904.3(CTNNB1): c.95A> C (p.Asp32Ala) single nucleotide variant Likely pathogenic rs121913396 GRCh37 Chromosome 3, 41266098: 41266098
48 CTNNB1 NM_001904.3(CTNNB1): c.95A> T (p.Asp32Val) single nucleotide variant Likely pathogenic rs121913396 GRCh37 Chromosome 3, 41266098: 41266098
49 CTNNB1 NM_001904.3(CTNNB1): c.98C> G (p.Ser33Cys) single nucleotide variant Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
50 CTNNB1 NM_001904.3(CTNNB1): c.100G> C (p.Gly34Arg) single nucleotide variant Likely pathogenic rs121913399 GRCh37 Chromosome 3, 41266103: 41266103

Copy number variations for Medulloblastoma from CNVD:

7 (show top 50) (show all 406)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13756 1 1 27800000 Deletion Medulloblastoma
2 13826 1 1 84700000 Deletion Medulloblastoma
3 13834 1 1 94500000 Deletion Medulloblastoma
4 14508 1 109116339 109116457 Amplification Medulloblastoma
5 15075 1 112496243 112497197 Deletion Medulloblastoma
6 16439 1 124300000 247249719 Gain Medulloblastoma
7 16481 1 125000000 249250621 Gain Medulloblastoma
8 18169 1 144250173 193504146 Gain Medulloblastoma
9 22567 1 167495768 167505182 Deletion Medulloblastoma
10 25322 1 187353840 187354239 Amplification Medulloblastoma
11 25794 1 194888508 194889123 Amplification Medulloblastoma
12 27709 1 211370717 247249719 Gain Medulloblastoma
13 28242 1 220443401 220443721 Deletion Medulloblastoma
14 29306 1 2300000 57866667 Deletion Medulloblastoma
15 29307 1 2300000 68700000 Deletion Medulloblastoma
16 31250 1 26333039 26333369 Deletion Medulloblastoma
17 31487 1 27800000 120700000 Deletion Medulloblastoma
18 31730 1 30200000 63811651 Gain Medulloblastoma
19 32194 1 34400000 43900000 Amplification Medulloblastoma
20 32220 1 34600000 44100000 Copy number MYCL1 Medulloblastoma
21 32880 1 40100000 44100000 Copy number MPL Medulloblastoma
22 35923 1 69500000 247249719 Gain Medulloblastoma
23 35940 1 69500000 88100000 Deletion Medulloblastoma
24 36295 1 73498586 73502199 Amplification Medulloblastoma
25 36488 1 76124315 76124455 Amplification Medulloblastoma
26 37038 1 84700000 92000000 Amplification Medulloblastoma
27 37523 1 92000000 247249719 Gain Medulloblastoma
28 38144 10 1 135374737 Deletion Medulloblastoma
29 38147 10 1 135374737 Gain Medulloblastoma
30 38152 10 1 20189475 Loss Medulloblastoma
31 38882 10 105700000 135374737 Deletion Medulloblastoma
32 40125 10 124341161 124341587 Deletion DMBT1 Medulloblastoma
33 41435 10 17998747 17999193 Deletion Medulloblastoma
34 41578 10 20890630 20897371 Deletion Medulloblastoma
35 42767 10 38815211 38909744 Amplification Medulloblastoma
36 42797 10 40200000 135534747 Loss Medulloblastoma
37 42805 10 40300000 135374737 Deletion Medulloblastoma
38 42892 10 42100000 135374737 Deletion Medulloblastoma
39 42906 10 42114131 42130982 Amplification Medulloblastoma
40 44229 10 53686068 53686625 Deletion Medulloblastoma
41 44331 10 55250865 57057708 Recurrent translocat ion PCDH15 Medulloblastoma
42 44628 10 60813485 133778458 Loss Medulloblastoma
43 44902 10 64800000 135374737 Deletion Medulloblastoma
44 45281 10 69738803 69739239 Deletion Medulloblastoma
45 47498 10 94192885 94194314 Deletion Medulloblastoma
46 48314 11 1 134452384 Deletion Medulloblastoma
47 48316 11 1 134452384 Gain Medulloblastoma
48 48367 11 1 36400000 Deletion Medulloblastoma
49 48483 11 1 48800000 Deletion Medulloblastoma
50 48690 11 101740351 101781327 Deletion BIRC2 Medulloblastoma

Expression for Medulloblastoma

Search GEO for disease gene expression data for Medulloblastoma.

Pathways for Medulloblastoma

Pathways related to Medulloblastoma according to GeneCards Suite gene sharing:

(show all 26)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.75 APC CTNNB1 GFAP GLI1 MYC NTRK3
2
Show member pathways
13.48 CTNNB1 GLI1 KCTD11 NTRK3 PTCH1 PTCH2
3 12.33 APC CTNNB1 MYC TP53
4
Show member pathways
12.27 APC CTNNB1 MYC TP53
5 12.09 APC CTNNB1 MYC TP53
6 12.04 BRCA2 CTNNB1 MYC TP53
7 12.03 CTNNB1 MYC PTCH1 SMO TP53
8 11.92 APC BRCA2 CTNNB1 GLI1 MYC PTCH1
9
Show member pathways
11.91 APC CTNNB1 GLI1 PTCH1 PTCH2 SMO
10 11.89 APC CTNNB1 GLI1 PTCH1 PTCH2 SUFU
11 11.86 APC CTNNB1 MYC TP53
12 11.8 APC CTNNB1 MYC TP53
13
Show member pathways
11.77 GLI1 PTCH1 PTCH2 SMO SUFU
14 11.71 CTNNB1 GFAP MYC ZIC1
15 11.69 APC CTNNB1 MYC
16 11.61 APC CTNNB1 MYC
17 11.59 MYC MYCN TP53
18 11.58 MYC NTRK3 TP53
19 11.48 APC CTNNB1 MYC
20 11.4 APC CTNNB1 MYC
21 11.29 GLI1 PTCH1 SMO
22 11.2 CTNNB1 MYC TP53
23
Show member pathways
11.13 PTCH1 PTCH2 SMO
24 11.07 CTNNB1 MYC TP53
25
Show member pathways
10.89 MYC OTX2 TP53
26 10.27 MYC MYCN

GO Terms for Medulloblastoma

Cellular components related to Medulloblastoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.83 APC BRCA2 CDCA7L CTNNB1 DAB2IP DMBT1
2 protein complex GO:0043234 9.77 BRCA2 CTNNB1 MYC OTX2 TP53
3 Wnt signalosome GO:1990909 9.32 APC CTNNB1
4 beta-catenin destruction complex GO:0030877 9.26 APC CTNNB1
5 catenin complex GO:0016342 9.16 APC CTNNB1
6 ciliary tip GO:0097542 8.8 GLI1 SMO SUFU

Biological processes related to Medulloblastoma according to GeneCards Suite gene sharing:

(show all 38)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.99 APC CTNNB1 DAB2IP NTRK3 TP53
2 positive regulation of cell proliferation GO:0008284 9.98 CDCA7L CTNNB1 GLI1 MYC MYCN NTRK3
3 multicellular organism development GO:0007275 9.96 DAB2IP DMBT1 GLI1 KCTD11 NTRK3 OTX2
4 in utero embryonic development GO:0001701 9.94 CTNNB1 MYC PTCH1 SMO
5 positive regulation of gene expression GO:0010628 9.93 CTNNB1 MYC MYCN NTRK3 SMO TP53
6 negative regulation of gene expression GO:0010629 9.91 CTNNB1 MYC MYCN SMO
7 smoothened signaling pathway GO:0007224 9.83 GLI1 PTCH1 SMO
8 regulation of growth GO:0040008 9.82 DAB2IP KCTD11 PTCH1
9 negative regulation of cell death GO:0060548 9.8 CTNNB1 MYC NTRK3
10 canonical Wnt signaling pathway GO:0060070 9.8 APC CTNNB1 GLI1 MYC
11 pattern specification process GO:0007389 9.79 PTCH1 SMO ZIC1
12 skin development GO:0043588 9.77 CTNNB1 PTCH2 SUFU
13 branching involved in ureteric bud morphogenesis GO:0001658 9.76 CTNNB1 MYC PTCH1
14 response to gamma radiation GO:0010332 9.73 BRCA2 MYC TP53
15 negative regulation of fibroblast proliferation GO:0048147 9.71 DAB2IP MYC TP53
16 renal system development GO:0072001 9.69 CTNNB1 PTCH1 SMO
17 mammary gland epithelial cell differentiation GO:0060644 9.67 PTCH1 SMO
18 regulation of osteoblast differentiation GO:0045667 9.67 CTNNB1 GLI1
19 dorsal/ventral neural tube patterning GO:0021904 9.67 PTCH1 SMO
20 dorsal/ventral pattern formation GO:0009953 9.67 CTNNB1 GLI1 PTCH1 SMO
21 cellular response to cholesterol GO:0071397 9.66 PTCH1 SMO
22 layer formation in cerebral cortex GO:0021819 9.66 CTNNB1 DAB2IP
23 negative regulation of astrocyte differentiation GO:0048712 9.65 MYCN NTRK3
24 cell fate determination GO:0001709 9.65 CTNNB1 PTCH1 PTCH2
25 negative regulation of cell division GO:0051782 9.63 MYC PTCH1
26 positive regulation of epidermal cell differentiation GO:0045606 9.62 PTCH1 PTCH2
27 positive regulation of mesenchymal cell proliferation GO:0002053 9.62 CTNNB1 MYC MYCN SMO
28 cerebellar cortex morphogenesis GO:0021696 9.61 GLI1 SMO
29 smoothened signaling pathway involved in regulation of cerebellar granule cell precursor cell proliferation GO:0021938 9.58 GLI1 SMO
30 epidermal cell fate specification GO:0009957 9.55 PTCH1 PTCH2
31 regulation of smoothened signaling pathway GO:0008589 9.46 GLI1 OTX2 PTCH1 ZIC1
32 positive regulation of transcription, DNA-templated GO:0045893 9.32 BRCA2 CTNNB1 GLI1 MYC MYCN OTX2
33 negative regulation of smoothened signaling pathway GO:0045879 9.26 KCTD11 PTCH1 PTCH2 SUFU
34 cell differentiation GO:0030154 10.11 CTNNB1 DMBT1 GLI1 KCTD11 NTRK3 TP53
35 negative regulation of transcription, DNA-templated GO:0045892 10.07 CTNNB1 DAB2IP PTCH1 SMO TP53
36 negative regulation of transcription from RNA polymerase II promoter GO:0000122 10.07 CTNNB1 DAB2IP MYC PTCH1 SMO SUFU
37 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.06 CTNNB1 DAB2IP GLI1 MYC MYCN OTX2
38 negative regulation of cell proliferation GO:0008285 10.04 APC CTNNB1 DAB2IP PTCH1 TP53

Molecular functions related to Medulloblastoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.88 APC DAB2IP GFAP KCTD11 SYP TP53
2 protein kinase binding GO:0019901 9.72 APC CTNNB1 DAB2IP SUFU TP53
3 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000978 9.65 CTNNB1 GLI1 MYC OTX2 ZIC1
4 patched binding GO:0005113 9.37 PTCH1 SMO
5 hedgehog family protein binding GO:0097108 9.16 PTCH1 PTCH2
6 hedgehog receptor activity GO:0008158 8.96 PTCH1 PTCH2
7 smoothened binding GO:0005119 8.62 PTCH1 PTCH2

Sources for Medulloblastoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67